OP Asset Management Ltd Purchases Shares of 3,718 Medpace Holdings, Inc. $MEDP

OP Asset Management Ltd purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,718 shares of the company’s stock, valued at approximately $1,785,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Optiver Holding B.V. bought a new position in Medpace during the third quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. Finally, Quarry LP acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $35,000. Institutional investors own 77.98% of the company’s stock.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. BMO Capital Markets cut their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Barclays decreased their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Robert W. Baird lowered their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $467.08.

Medpace Stock Performance

Shares of MEDP opened at $527.07 on Monday. The stock has a market cap of $15.05 billion, a PE ratio of 33.13, a PEG ratio of 2.67 and a beta of 1.18. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The stock has a 50 day simple moving average of $451.19 and a 200-day simple moving average of $496.65.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the firm earned $3.67 EPS. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.